EBIT Margin: Earnings before interest and taxes as a portion of total revenues. Calculated as: EBIT / Total Revenues
Oncternal Therapeutics, Inc. (ONCT) had EBIT Margin of -1542.88% for the most recently reported fiscal quarter, ending 2024-03-31.
| Income Statement Financials | |
$0.57M |
|
$-8.39M |
|
-- |
|
$0.57M |
|
$9.35M |
|
$-8.78M |
|
$0.39M |
|
$-8.39M |
|
$-8.39M |
|
$-8.39M |
|
$-8.39M |
|
$-8.39M |
|
$-8.39M |
|
$-8.78M |
|
$-9.09M |
|
2.96M |
|
2.96M |
|
$-2.83 |
|
$-2.83 |
|
| Balance Sheet Financials | |
$28.50M |
|
-- |
|
$0.64M |
|
$29.14M |
|
$6.12M |
|
-- |
|
$0.10M |
|
$6.21M |
|
$22.93M |
|
$22.93M |
|
$22.93M |
|
2.96M |
|
| Cash Flow Statement Financials | |
$-7.44M |
|
$7.22M |
|
$-0.09M |
|
$6.70M |
|
$6.40M |
|
$-0.30M |
|
$1.36M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1542.88% |
|
|
EBIT Margin |
-1542.88% |
-- |
|
-1474.16% |
|
-1474.16% |
|
$-7.44M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
-- |
|
-- |
|
-36.59% |
|
-36.59% |
|
-28.78% |
|
-36.59% |
|
$7.75 |
|
$-2.51 |
|
$-2.51 |
|